Gene Therapy Promise Falls Flat Due to Economics
A 57-year-old man with a rare inherited disease was the only patient to receive a groundbreaking gene editing treatment. Now, the company behind it has abandoned efforts due to high costs, leaving him and another patient in limbo. A gene therapy for a rare inherited disease was tested on two patients at the National Institutes … Read more